PharmaResources (Shanghai) Co. Ltd. A (301230) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of PharmaResources (Shanghai) Co. Ltd. A stock ¥8.36, price ¥30.79, upside -72.8%, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
48‑month range ¥13.25 – ¥50.27 · fair‑value band ¥7.62 – ¥10.88 · the ¥30.79 price screens above the ¥8.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow PharmaResources (Shanghai) Co. Ltd. A in your weekly email
Every Wednesday you see whether PharmaResources (Shanghai) Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China.
Show moreShow less
It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.
PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China
Stock analysis
PharmaResources (Shanghai) Co. Ltd. A (301230) currently trades at ¥30.79, while our model-based Fair Value estimate is ¥8.36, 72.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥6.92 per share, and 0 of the 26 models we run sit above the ¥30.79 price.
Bear case: the Asset-Based group reads lowest at ¥1.50, and 26 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥7.62 (bear) to ¥10.88 (bull), the price of ¥30.79 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PharmaResources (Shanghai) Co. Ltd. A reported revenue of 688M CNY in FY2025 versus 448M CNY in FY2021, a compound +11.3%/yr. Reported net income was 34.3M CNY in FY2025, compounding −17.4%/yr from FY2021.
Key figures
Market cap 5.4B CNY (≈ $806M) Small · P/E ratio 219.9 · P/S ratio 7.40 · EPS (TTM) ¥0.1400 · Dividend yield 0.5% · Net margin 4.0% · Return on equity 2.8% · Return on assets (EBIT) 5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −73%, 301230 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥1.50 to ¥24.76). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥7.62Fair Value ¥8.36Bull¥10.88
Price ¥30.79 · Upside -72.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+26.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−15.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.9%
Dividend (yield on the price)0.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 6%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +28.4% a year for the price.
Compare PharmaResources (Shanghai) Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 595 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−72.8% · Bottom 25%
Profitability
Return on equity (12 months)2.8% · Above median
Return on assets2.6% · Above median
Net margin (12 months)4.0% · Below median
Operating margin (12 months)5.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)15.3% · Above median
Dividend yield (12 months)0.5% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)219.9× · Priciest 25%
P/B5.34× · Priciest 25%
P/S (12 months)7.40× · Pricier than median
Price / free cash flow58.2× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)77· sector 0
PAST (return on equity)11· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)10· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PharmaResources (Shanghai) Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/301230
Frequently asked questions
Is PharmaResources (Shanghai) Co. Ltd. A (301230) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of ¥8.36 versus a price of ¥30.79, about −73% upside (overvalued).
What is the fair value of 301230?
Our model-based fair value for PharmaResources (Shanghai) Co. Ltd. A is ¥8.36 (as of Oct 27, 2026), built from audited fundamentals. The current price: ¥30.79.
What is the quality score of 301230?
PharmaResources (Shanghai) Co. Ltd. A has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PharmaResources (Shanghai) Co. Ltd. A (301230)?
Our model-based price target is the fair value of ¥8.36 (as of Oct 27, 2026) from 26 valuation models. Cautious scenario ¥7.62, optimistic scenario ¥10.88. It is a calculation from audited fundamentals, not an analyst target.
What is the PharmaResources (Shanghai) Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥8.36, about −73% upside versus a price of ¥30.79 (overvalued). Cautious scenario ¥7.62, optimistic scenario ¥10.88. The calculation is refreshed regularly with new filings.
What is the revenue of PharmaResources (Shanghai) Co. Ltd. A (301230)?
PharmaResources (Shanghai) Co. Ltd. A reported trailing-twelve-month revenue of about 725M CNY (latest available figure, as of Oct 27, 2026).
Does PharmaResources (Shanghai) Co. Ltd. A pay a dividend?
PharmaResources (Shanghai) Co. Ltd. A currently shows a dividend yield of 0.50% relative to its recent price (as of Oct 27, 2026).
What growth is priced into PharmaResources (Shanghai) Co. Ltd. A (301230)?
For today's price to be fair in a discounted-cash-flow model, PharmaResources (Shanghai) Co. Ltd. A would have to grow free cash flow by +30.6 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.5 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of 301230 use?
Our models discount PharmaResources (Shanghai) Co. Ltd. A at 11.6 %: a base by market capitalisation (small), damped by beta 0.88, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PharmaResources (Shanghai) Co. Ltd. A that is +30.6 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has PharmaResources (Shanghai) Co. Ltd. A (301230) delivered so far?
Over the past 5 years revenue at PharmaResources (Shanghai) Co. Ltd. A grew +19.5 % a year. The price currently implies +30.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PharmaResources (Shanghai) Co. Ltd. A (301230) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into PharmaResources (Shanghai) Co. Ltd. A (+30.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The free-cash-flow yield on the price is 2.15 %: that much free cash flow PharmaResources (Shanghai) Co. Ltd. A produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PharmaResources (Shanghai) Co. Ltd. A (301230)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PharmaResources (Shanghai) Co. Ltd. A it is ¥8.36 per share (as of Oct 27, 2026), against a price of ¥30.79. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is PharmaResources (Shanghai) Co. Ltd. A stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 301230 trades above its calculated fair value: price ¥30.79, fair value ¥8.36, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301230?
No. The price is what the market pays today (¥30.79); the fair value is what the company's own numbers justify (¥8.36). For PharmaResources (Shanghai) Co. Ltd. A the two are ¥22.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is PharmaResources (Shanghai) Co. Ltd. A worth?
The market values PharmaResources (Shanghai) Co. Ltd. A at about 5.4B CNY (market capitalisation, as of Oct 27, 2026). Per share that is ¥30.79; our models calculate a fair value of ¥8.36 per share.
What do the bullish and bearish scenarios say about 301230?
Our models span a range for PharmaResources (Shanghai) Co. Ltd. A: cautious scenario ¥7.62, base ¥8.36, optimistic ¥10.88 per share (as of Oct 27, 2026, price ¥30.79). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301230?
PharmaResources (Shanghai) Co. Ltd. A trades at a price-to-earnings ratio of 219.9 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥8.36 is built from several models across several years. Other multiples: P/B 5.3, P/S 7.4.
How solid is the balance sheet of PharmaResources (Shanghai) Co. Ltd. A (301230)?
Balance-sheet figures for PharmaResources (Shanghai) Co. Ltd. A (as of Oct 27, 2026): return on equity 2.8%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 301230 from its 52-week high?
PharmaResources (Shanghai) Co. Ltd. A trades at ¥30.79, about 39% below its 52-week high of ¥50.27 and 37% above the low of ¥22.41 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of ¥8.36 is for.
Which stocks are comparable to PharmaResources (Shanghai) Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PharmaResources (Shanghai) Co. Ltd. A stock attractive at the current price?
The data as of Oct 27, 2026: price ¥30.79, calculated fair value ¥8.36 (−73%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301230 calculated?
We run PharmaResources (Shanghai) Co. Ltd. A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥8.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. PharmaResources (Shanghai) Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The closing price on Oct 28, 2026 was ¥30.79. Our model-based fair value is ¥8.36, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PharmaResources (Shanghai) Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥10.88). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of PharmaResources (Shanghai) Co. Ltd. A
How large is the market capitalisation of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The market capitalisation of PharmaResources (Shanghai) Co. Ltd. A is 5.4B CNY (≈ $806M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The price-to-sales ratio of PharmaResources (Shanghai) Co. Ltd. A is 7.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PharmaResources (Shanghai) Co. Ltd. A (301230)?
Earnings per share at PharmaResources (Shanghai) Co. Ltd. A are ¥0.1400 (price ÷ EPS = P/E 219.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The dividend yield of PharmaResources (Shanghai) Co. Ltd. A is 0.5% (payout 110%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The net margin of PharmaResources (Shanghai) Co. Ltd. A is 4.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The return on equity (ROE) of PharmaResources (Shanghai) Co. Ltd. A is 2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PharmaResources (Shanghai) Co. Ltd. A (301230)?
On an EBIT basis the return on assets of PharmaResources (Shanghai) Co. Ltd. A is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PharmaResources (Shanghai) Co. Ltd. A (301230)?
The operating margin of PharmaResources (Shanghai) Co. Ltd. A is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PharmaResources (Shanghai) Co. Ltd. A (301230)?
Revenue at PharmaResources (Shanghai) Co. Ltd. A is growing +15.3% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PharmaResources (Shanghai) Co. Ltd. A (301230)?
Earnings per share at PharmaResources (Shanghai) Co. Ltd. A are growing −96.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch PharmaResources (Shanghai) Co. Ltd. A in the live analysis
One click puts PharmaResources (Shanghai) Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 27, 2026